Healthcare
Edwards Lifesciences Corporation(EW)
Live Price
Offline$87.36
+0.78% today
1Y Change
+13.50%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $47.97B
- Revenue Growth
- +11.5%
- EPS Growth
- -73.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Edwards Lifesciences Corporation (EW) is a Healthcare stock with a market cap of $47.97B and listed on NYSE. The stock last traded around $87.36 and up 13.5% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +11.5%, EPS growth of -73.6%, a dividend yield of 0.0%. What stands out right now is revenue +11.5%, EPS -73.6%, free cash flow +360.5% with operating margin 27.6% and ROIC 12.1%. Valuation already assumes a fairly strong business story at P/E 44.1 and price/sales 7.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.5% vs +7.6% peer median
Operating Margin
Above sector median
+27.6% vs +19.4% peer median
P/E
Above sector median
44.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 22, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +11.5% and EPS is at -73.6%, with operating margin around 27.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 22, 2026 | โ | -2.2% | -0.4% | +1.8% |
2026 Feb 10, 2026 | -6.2% | +3.0% | +2.5% | +10.4% |
2025 Oct 30, 2025 | +12.4% | -1.2% | -1.2% | +3.8% |
Benchmark Edge
EW vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EW
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EW Max Drawdown
-12.73%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EW and SPY.
Company Overview
Edwards Lifesciences Corporation
New York Stock Exchange
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
- Leadership
- Bernard J. Zovighian
- IPO Date
- Mar 27, 2000
- Employees
- 15.8k
- Street Address
- One Edwards Way
- Mailing
- Irvine, CA, 92614
- Region
- Irvine, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 250 2500
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 44.1
- EV/EBITDA
- 32.2
- Price/Sales
- 7.6
- Price/Book
- 4.7
Growth
- Revenue
- +11.5%
- EPS
- -73.6%
- Free Cash Flow
- +360.5%
Profitability
- Gross Margin
- 78.0%
- Operating Margin
- 27.6%
- Net Margin
- 17.3%
- ROE
- 10.6%
- ROIC
- 12.1%
Balance Sheet
- Debt/Equity
- 0.07
- Current Ratio
- 4.42
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.